Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Clear Filters

Search Clinical Trials

103 Results
Completed
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
This is a phase I trial to assess the safety of a dose escalation of hCD40L-expressing autologous tumor cells with a fixed dose of recombinant hIL-2 gene transduced autologous leukemic …
Baylor Role: Lead Sponsor
Completed
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells
Before starting treatment some of the cancer cells will be taken from the patient and separated in the laboratory. A specially produced human virus (adenovirus) that carries the IL-2 gene …
Baylor Role: Lead Sponsor
Completed
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
CAMPATH-1H will be given as a daily IV infusion for three days. Fludarabine will be given as a daily IV infusion for four days. Anti-CD45 will be given as a …
Baylor Role: Lead Sponsor
Completed
The Role of Amylin and Glucagon in T1DM
Objective: To develop a new treatment approach in the prevention of hypo and hyperglycemia in children with type 1diabetes. Background/Rationale: The diabetes control and complications trial (DCCT) showed that improving …
Baylor Role: Lead Sponsor
Terminated
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) …
Baylor Role: Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role: Lead Sponsor
Terminated
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
Patients will have received a haplo-identical stem cell transplant on our on-going study "CD45 (YTH-24 and YTH-54) and CD52 (Campath 1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell …
Baylor Role: Lead Sponsor
Terminated
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Before patients receive any treatments, they will have the following: - Complete history and physical exam - Dental consultation - Bone marrow aspirate - Blood tests - Urinanalysis - Tests …
Baylor Role: Lead Sponsor
Terminated
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
We expect that the patient's participation in this study will last approximately 18 months to 2 years. Before treatment begins, they will be evaluated to confirm they meet the requirements …
Baylor Role: Lead Sponsor
Completed
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
After subjects have completed the pretreatment evaluations, they will receive an injection of Enbrel - the study drug -(given under the skin) twice weekly. If the subjects disease stabilizes or …
Baylor Role: Lead Sponsor